Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
Infectious Disease
•
Immunosuppression
•
MRSA
What is your approach to a patient on immunosuppressants with an outpatient cutaneous MRSA infection or to a MRSA carrier?
Related Questions
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Is there any role for administering another course of recombinant zoster vaccine (Shingrix) in a previously vaccinated patient with RA, who is in clinical remission on JAK inhibitor but has had a breakthrough shingles infection?
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How often do you see bony erosions in patients with Lyme arthritis?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
